OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Moses, Robert Kamya

eRA COMMONS USER NAME (credential, e.g., agency login): mkamya

POSITION TITLE: Professor of Medicine, School of Medicine, Makerere University, Kampala, Uganda.

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

| INSTITUTION AND LOCATION | DEGREE(if applicable) | Completion DateMM/YYYY | FIELD OF STUDY |
| --- | --- | --- | --- |
| Makerere University, Kampala, Uganda | MBChB | 06/1985 | Medicine and Surgery |
| Makerere University, Kampala, Uganda | M.Med/Residency | 06/1991 | Internal Medicine |
| University of California, Berkeley, CA | MPH | 06/1995 | Epidemiology |
| University of Antwerp, Belgium | PHD | 06/2009 | Biomedical Sciences |

**A. Personal Statement**

I am a Professor of Medicine, past Dean of the School of Medicine and past Chair of the Department of Medicine at Makerere University in Kampala, Uganda. I am a central figure in training at multiple levels at Makerere University. I have been involved in HIV care and research in Uganda for over 25 years and in malaria research since 1998. For over 20 years, we have conducted multiple clinical, molecular, epidemiologic, immunologic and entomologic research projects with American and European investigators on malaria, HIV and other infectious diseases in Uganda and have published over 500 papers in peer reviewed journals. I am the director of the Uganda Malaria Surveillance Program (UMSP) which was established in 2006 by Uganda Health Scientists in collaboration with UCSF and the National Malaria Control Division (NMCD). Over the past fifteen years, the UMSP has been collecting high quality malaria surveillance data from government-run health facilities around the country and providing information to enable evidence-based national malaria control and policy. I am the Director of the Infectious Diseases Research Collaboration (IDRC [www.idrc-uganda.org](http://www.idrc-uganda.org)) which has memorandum of understanding with Makerere University, UCSF and the Uganda Ministry of Health. I chair the Uganda Ministry of Health National AIDS Advisory Committee. I also serve on the Scientific Advisory and Case Management Committees of the Uganda MoH COVID-19 response.

**Ongoing and recently completed projects that I would like to highlight include:**

U01AI150510-01A1

Havlir, Kamya, Petersen (MPIs)

09/25/2020 – 06/30/2025

A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa

1U19AI089674

Dorsey (PI), Role: Co-Investigator

7/1/10-3/31/24

International Centers of Excellence for Malaria Research: Program for Resistance, Immunology, Surveillance and Modeling of Malaria in Uganda.

FAA No. 72061720FA00002

Kamya and Westercamp (MPIs)

08/12/2020 – 08/11/2023.

PMI/Uganda Housing Modification Study and Enhanced Entomological Surveillance Activity. (HMS-EES)

1U01AI141308

Dorsey/Rosenthal (MPIs), Role: Co-Investigator

4/15/20-3/31/25

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda

CSA2018HS- 2518

Kabami, Kamya (MPIs)

03/01/2020- 02/28/2025

EDCTP: Leveraging the HIV Platform for Hypertension Control in Uganda

D43 TW010526-01

Kamya/Dorsey (MPIs)

06/01/17-02/28/22

## Training in Malaria Surveillance, Epidemiology and Implementation Science Research to Strengthen Malaria Policy and Control in Uganda

2D43 TW010037-06

Kamya/Semitala (MPIs)

05/2021–03/2026

Building Implementation Science Capacity at Makerere University to Strengthen the Response to the HIV/AIDS Epidemic in Uganda

D43TW011304

Kamya/Katahoire/Camlin (MPIs)

09/01/19-03/31/24

Strengthening behavioral and social science research capacity to address the evolving challenges in HIV AIDS care and prevention in Uganda

**Citations:**

1. **Kamya MR**, Kakuru A, Muhindo M, Arinaitwe E, Nankabirwa JI, Rek J, Bigira V, Kapisi J, Wanzira H, Achan J, Natureeba P, Gasasira A, Havlir D, Jagannathan P, Rosenthal PJ, Rodriguez-Barraquer I, Dorsey G.[The Impact of Control Interventions on Malaria Burden in Young Children in a Historically High-Transmission District of Uganda: A Pooled Analysis of Cohort Studies from 2007 to 2018.](https://pubmed.ncbi.nlm.nih.gov/32431280/) Am J Trop Med Hyg. 2020 Aug;103(2):785-792. PMID: 32431280; PMCID: PMC7410449.
2. Kwarisiima D, Atukunda M, Owaraganise A, Chamie G, Clark T, Kabami J, Jain V, Byonanebye D, Mwangwa F, Balzer LB, Charlebois E, **Kamya MR**, Petersen M, Havlir DV, Brown LB. Hypertension control in integrated H.I.V. and chronic disease clinics in Uganda in the SEARCH study. B.M.C. Public Health. 2019 May 6;19(1):511. doi: 10.1186/s12889-019-6838-6. PubMed PMID: 31060545; PubMed Central PMCID: PMC6501396.
3. Nankabirwa JI, Briggs J, Rek J, Arinaitwe E, Nayebare P, Katrak S, Staedke SG, Rosenthal PJ, Rodriguez-Barraquer I, **Kamya MR**, Dorsey G, Greenhouse B. [Persistent parasitemia despite dramatic reduction in malaria incidence after 3 rounds of indoor residual spraying in Tororo, Uganda.](https://www.ncbi.nlm.nih.gov/pubmed/30383230) The Journal of infectious diseases. 2018; PubMed [journal] PMID: 30383230
4. **Kamya, Moses**; Arinaitwe, Emmanuel; Wanzira, Humphrey; Katureebe, Agaba; Barusya, Chris; Kigozi, Simon; Kilama, Maxwell; Tatem, Andrew; Rosenthal, Philip; Drakeley, Chris; Lindsay, Steve; Staedke, Sarah; Smith, David; Greenhouse, Bryan; Dorsey, Grant. Malaria Transmission, Infection and Disease at Three Sites with Varied Transmission Intensity in Uganda: Implications for Malaria Control. Am J Trop Med Hyg, 2015. **92**(5): p. 903-12.  PubMed PMID: 25778501; PubMed Central PMCID: PMC4426576.

**B. Positions, Scientific Appointments, and Honors**

1986-1987: Intern, Depts. of Internal Medicine and OBGYN, Mulago Hospital, Kampala, Uganda

1987-1988: Casualty Officer, Mulago Hospital, Kampala, Uganda

1991-1992: Consulting physician, STD Clinic, Mulago Hospital, Kampala, Uganda

1992-1999: Lecturer Department of Medicine, Makerere University/Mulago Hospital

1997-Present: Projector Director: MU-UCSF Research Collaboration

1999-2007: Senior Lecturer, Department of Medicine, Makerere Medical School, Kampala, Uganda

2005-Present: Director, Uganda Malaria Surveillance Project

2007-2009: Associate Professor, Department of Medicine, Makerere University, Uganda

2009-current: Professor, Dept. of Medicine, Makerere University School of Medicine, Kampala, Uganda

2007-2010: Head, Infectious Disease Unit, Mulago Hospital, Kampala, Uganda

2008-current: Executive Director, Infectious Diseases Research Collaboration, Uganda

2009-2015: Chair, Dept of Medicine, Makerere University School of Medicine, Kampala, Uganda

2015-2019: Dean, Makerere University School of Medicine, Kampala, Uganda

2019-current: Professor of Medicine, Makerere University School of Medicine, Kampala, Uganda

In 2018, I was awarded the University of California Berkeley (UCB) School of Public Health honor as one of the 75 most influential public health alumni over UCB 75-year history.

2019: American Society of Hygiene and Tropical Medicine (ASTMH) Commemorative Fund Lecture: The prospects of eliminating malaria in high burden African countries.

**C. Contribution to Science**

1. My work in malaria research significantly contributed to shaping the malaria treatment policy in Uganda by providing information to enable evidence-based national policy on antimalarial recommendation. My earlier work on efficacy of different antimalarial treatments in Uganda contributed to the evidence base for change from monotherapies to combination therapy and finally to the use of artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.
2. **Kamya MR**, Dorsey G, Gasasira A, Ndeezi G, Babirye JN, Staedke SG, Rosenthal PJ.The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Trans R Soc Trop Med Hyg. 2001 Jan-Feb;95(1):50-5. PMID: 1128006
3. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, **Kamya MR**. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. American Journal of Tropical Medicine and Hygiene 2003;2(6) 68:127-32.
4. **Kamya MR**, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007 May 18;2(5):e20. PubMed PMID:17525792; PubMed Central PMCID: PMC1876597.
5. In addition to the contributions described above, with a team of collaborators, I studied the interaction of Malaria and HIV infection, which are among the most important infectious diseases worldwide. Given the overlapping epidemics of malaria and HIV in sub-Saharan Africa, we undertook a series of studies looking at interactions between malaria and HIV, will a focus on the role of trimethoprim-sulfamethoxazole (TS) prophylaxis and interactions between antimalarial drugs and antiretrovirals. These studies informed guidelines for the management of malaria in HIV infected populations.
	1. **Kamya MR**, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis. 2006 Jan 1;193(1):9-15. Epub 2005 Nov 18. PubMed PMID: 16323126.
	2. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, **Kamya MR**. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29;367(22):2110-8. doi: 10.1056/NEJMoa1200501. PubMed PMID: 23190222; PubMed Central PMCID: PMC3664297.
	3. **Kamya MR**, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28;28(18):2701-2709.PMID: 25493596
6. Despite the high burden of malaria and the recent increase in funding for control efforts in countries like Uganda, quality malaria surveillance data to monitor temporal trends and the impact of population level interventions is limited. Our work in malaria research has significantly contributed to the understanding of malaria epidemiology and control in Uganda by providing information to enable evidence-based national malaria control and policy. Through our ICEMR program and other funding mechanisms we have implemented a variety of high-quality malaria surveillance programs and implementation studies. These projects have generated a wealth of data to better define spatial and temporal trends in the burden of malaria around Uganda and measure the impact of population level control interventions.
7. Staedke SG, Gonahasa S, Dorsey G, **Kamya MR**, Maiteki-Sebuguzi C, Lynd A, Katureebe A, Kyohere M, Mutungi P, Kigozi SP, Opigo J, Hemingway J, Donnelly MJ. [Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign.](https://www.ncbi.nlm.nih.gov/pubmed/32305094) *Lancet* 2020; 395(10232):1292-1303. PMID: 32305094; PMCID: PMC7181182.
8. Nankabirwa JI, Briggs J, Rek J, Arinaitwe E, Nayebare P, Katrak S, Staedke SG, Rosenthal PJ, Rodriguez-Barraquer I, **Kamya MR**, Dorsey G, Greenhouse B. [Persistent parasitemia despite dramatic reduction in malaria incidence after 3 rounds of indoor residual spraying in Tororo, Uganda.](https://www.ncbi.nlm.nih.gov/pubmed/30383230) *J Infect Dis* 2018; 219(7):1104-1111. PMID: 30383230; PMCID: PMC6420168.
9. Katureebe A, Zinszer K, Arinaitwe E, Rek J, Kakande E, Charland K, Kigozi R, Kilama M, Nankabirwa J, Yeka A, Mawejje H, Mpimbaza A, Katamba H, Donnelly MJ, Rosenthal PJ, Drakeley C, Lindsay SW, Staedke SG, Smith DL, Greenhouse B, Kamya MR, **Dorsey G**. [Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study.](https://www.ncbi.nlm.nih.gov/pubmed/27824885) *PLoS Medicine* 2016;13(11):e1002167. PMID: 27824885; PMCID: PMC5100985.
10. In addition to the above, our research has significantly contributed to the understanding of malaria in pregnancy by providing information to enable evidence-based malaria in pregnancy control and policy. Given the high burden of malaria among pregnant women and children living in highly endemic areas of Africa, we have conducted a series of clinic trials evaluating different chemoprevention regimens. These studies have shown that DP has been the most effective drug for the prevention of malaria in our study sites.
11. Kajubi R, Ochieng T, Kakuru A, Jagannathan P, Nakalembe M, Ruel T, Opira B, Ochokoru H, Ategeka J, Nayebare P, Clark TD, Havlir DV, **Kamya MR**, Dorsey G. [Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.](https://www.ncbi.nlm.nih.gov/pubmed/30910321/)Lancet. 2019 Apr 6;393(10179):1428-1439. doi: 10.1016/S0140-6736(18)32224-4. Epub 2019 Mar 22. PubMed PMID: 30910321.
12. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opira B, Olwoch P, Ategeka J, Nayebare P, Clark TD, Feeney ME, Charlebois ED, Rizzuto G, Muehlenbachs A, Havlir DV, **Kamya MR**, Dorsey G. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. *N Engl J Med*. 2016;374(10):928-939. doi:10.1056/NEJMoa1509150. PubMed PMID: 26962728; PubMed Central PMCID: PMC4847718.
13. Jagannathan P, Kakuru A, Okiring J, Muhindo MK, Natureeba P, Nakalembe M, Opira B, Olwoch P, Nankya F, Ssewanyana I, Tetteh K, Drakeley C, Beeson J, Reiling L, Clark TD, Rodriguez-Barraquer I, Greenhouse B, Wallender E, Aweeka F, Prahl M, Charlebois ED, Feeney ME, Havlir DV, **Kamya MR**, Dorsey G. [Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/30016328) PLoS medicine. 2018; 15(7):e1002606. PubMed [journal] PMID: 30016328 PMCID: PMC6049882
14. In addition to malaria work, I am co-PI in the Sustainable East Africa Research in Community Health (SEARCH) collaboration. This work offered population-wide HIV testing, and multi-disease diagnostic, referral, treatment and prevention services and is currently conducting multiple trials to allow the design of strategies to Address Persistent Drivers of the HIV Epidemic in East Africa. The results of this work have informed HIV care and programs in Africa and the HIV field in general.
15. **Kamya MR,** Petersen ML, Kabami J, Ayieko J, Kwariisima D, Sang N, Clark TD, Schwab J, Charlebois ED, Cohen CR, Bukusi EA, Peng J, Jain V, Chen YH, Chamie G, Balzer LB, Havlir DV. SEARCH Human Immunodeficiency Virus (HIV) Streamlined Treatment Intervention Reduces Mortality at a Population Level in Men With Low CD4 Counts. Clin Infect Dis. 2021 Mar 30:ciaa1782. doi: 10.1093/cid/ciaa1782. Epub ahead of print. PMID: 33783495.
16. Havlir DV, Balzer LB, Charlebois ED, et al…Bukusi E, Kamya MR, Petersen M. [HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.](https://www.ncbi.nlm.nih.gov/pubmed/31314966/)N Engl J Med. 2019 Jul 18;381(3):219-229. doi: 10.1056/NEJMoa1809866. PubMed PMID: 31314966; PubMed Central PMCID: PMC6748325.
17. Petersen M, Balzer L, Kwarisiima D, Sang N, Chamie G, Ayieko J, Kabami J, Owaraganise A, Liegler T, Kadede K, Jain V, Plenty A, Brown L, Lavoy G, Schwab J, Black D, van der Laan M, Bukusi EA, Cohen CR, Clark TD, Charlebois E, **Kamya M,** Havlir D. Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa. JAMA. 2017 Jun 6: 317(21): 2196-2206. PMID: 28586888.
18. In addition to the SEARCH work, I have also been involved in HIV prevention research. There is a great need for innovative prevention strategies to address the persistent drivers of HIV transmission in high HIV risk populations, if we are to eliminate HIV by 2030. Our studies have contributed to our knowledge of HIV in these areas.
19. Puryear SB, Balzer LB, Ayieko J, Kwarisiima D, Hahn JA, Charlebois ED, Clark TD, Cohen CR, Bukusi EA, **Kamya MR**, Petersen ML, Havlir DV, Chamie G. Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. AIDS. 2020 Mar 1;34(3):405-413. doi: 10.1097/QAD.0000000000002427. PubMed PMID: 31725431; PubMed Central PMCID: PMC7046088.
20. Ayieko J, Petersen ML, Kabami J, Mwangwa F, Opel F, Nyabuti M, Charlebois ED, Peng J, Koss CA, Balzer LB, Chamie G, Bukusi EA, Kamya MR, Havlir DV. [Uptake and outcomes of a novel community-based HIV post-exposure prophylaxis (PEP) programme in rural Kenya and Uganda.](https://www.ncbi.nlm.nih.gov/pubmed/34152067/)J Int AIDS Soc. 2021 Jun;24(6):e25670. doi: 10.1002/jia2.25670. PubMed PMID: 34152067; PubMed Central PMCID: PMC8215805.
21. Koss CA, Havlir DV, Ayieko J, Kwarisiima D, Kabami J, Chamie G, Atukunda M, Mwinike Y, Mwangwa F, Owaraganise A, Peng J, Olilo W, Snyman K, Awuonda B, Clark TD, Black D, Nugent J, Brown LB, Marquez C, Okochi H, Zhang K, Camlin CS, Jain V, Gandhi M, Cohen CR, Bukusi EA, Charlebois ED, Petersen ML, Kamya MR, Balzer LB. [HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.](https://www.ncbi.nlm.nih.gov/pubmed/33561143/)PLoS Med. 2021 Feb;18(2):e1003492. doi: 10.1371/journal.pmed.1003492. eCollection 2021 Feb. PubMed PMID: 33561143; PubMed Central PMCID: PMC7872279.
22. I have built capacity for research for early career researchers through training, mentorship, supervision and providing opportunities for both local and international exposure. Research from these students has led to significant advance in the knowledge in Malaria, HIV and NCDs. This has also contributed to improving in-country expertise in research.
	1. Muhindo MK, Jagannathan P, Kakuru A, Opira B, Olwoch P, Okiring J, Nalugo N, Clark TD, Ruel T, Charlebois E, Feeney ME, Havlir DV, Dorsey G, **Kamya MR**. [Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/31307883/)Lancet Infect Dis. 2019 Sep;19(9):962-972. doi: 10.1016/S1473-3099(19)30299-3. Epub 2019 Jul 12. PubMed PMID: 31307883; PubMed Central PMCID: PMC6722008.
	2. Agaba BB, Yeka A, Nsobya S, Arinaitwe E, Nankabirwa J, Opigo J, Mbaka P, Lim CS, Kalyango JN, Karamagi C, **Kamya MR.** [Systematic review of the status of pfhrp2 and pfhrp3 gene deletion, approaches and methods used for its estimation and reporting in Plasmodium falciparum populations in Africa: review of published studies 2010-2019.](https://www.ncbi.nlm.nih.gov/pubmed/31694718/)Malar J. 2019 Nov 6;18(1):355. doi: 10.1186/s12936-019-2987-4. PubMed PMID: 31694718; PubMed Central PMCID: PMC6836395.
	3. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, **Kamya MR.** Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis. 2014 May;58(10):1404-12. doi: 10.1093/cid/ciu150. Epub 2014 Mar 12. PMID: 24621953

## Complete List of Published Work in MyBibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/moses.kamya.2/bibliography/public/>